Elicio Therapeutics Statistics
Total Valuation
ELTX has a market cap or net worth of $79.90 million. The enterprise value is $70.56 million.
| Market Cap | 79.90M |
| Enterprise Value | 70.56M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ELTX has 26.28 million shares outstanding. The number of shares has increased by 23.82% in one year.
| Current Share Class | 26.28M |
| Shares Outstanding | 26.28M |
| Shares Change (YoY) | +23.82% |
| Shares Change (QoQ) | +5.67% |
| Owned by Insiders (%) | 21.61% |
| Owned by Institutions (%) | 16.24% |
| Float | 19.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.39 |
| P/TBV Ratio | 10.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 1.78.
| Current Ratio | 2.77 |
| Quick Ratio | 2.55 |
| Debt / Equity | 1.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.00 |
Financial Efficiency
Return on equity (ROE) is -774.56% and return on invested capital (ROIC) is -122.09%.
| Return on Equity (ROE) | -774.56% |
| Return on Assets (ROA) | -77.88% |
| Return on Invested Capital (ROIC) | -122.09% |
| Return on Capital Employed (ROCE) | -171.36% |
| Weighted Average Cost of Capital (WACC) | 13.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.98% in the last 52 weeks. The beta is 1.88, so ELTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.88 |
| 52-Week Price Change | -72.98% |
| 50-Day Moving Average | 3.78 |
| 200-Day Moving Average | 8.33 |
| Relative Strength Index (RSI) | 40.60 |
| Average Volume (20 Days) | 279,478 |
Short Selling Information
The latest short interest is 1.75 million, so 6.65% of the outstanding shares have been sold short.
| Short Interest | 1.75M |
| Short Previous Month | 1.88M |
| Short % of Shares Out | 6.65% |
| Short % of Float | 9.11% |
| Short Ratio (days to cover) | 1.84 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -37.92M |
| Pretax Income | -37.84M |
| Net Income | -37.84M |
| EBITDA | -37.74M |
| EBIT | -37.92M |
| Earnings Per Share (EPS) | -$2.17 |
Balance Sheet
The company has $23.48 million in cash and $14.15 million in debt, with a net cash position of $9.33 million or $0.36 per share.
| Cash & Cash Equivalents | 23.48M |
| Total Debt | 14.15M |
| Net Cash | 9.33M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 7.94M |
| Book Value Per Share | 0.36 |
| Working Capital | 16.28M |
Cash Flow
In the last 12 months, operating cash flow was -$37.69 million and capital expenditures -$16,000, giving a free cash flow of -$37.71 million.
| Operating Cash Flow | -37.69M |
| Capital Expenditures | -16,000 |
| Depreciation & Amortization | 180,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -37.71M |
| FCF Per Share | -$1.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.82% |
| Shareholder Yield | -23.82% |
| Earnings Yield | -47.36% |
| FCF Yield | -47.20% |
Analyst Forecast
The average price target for ELTX is $16.50, which is 442.76% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.50 |
| Price Target Difference | 442.76% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |